Organization Profile

You just read:

New PD-1 immune checkpoint inhibitor Opdivo (nivolumab) first to demonstrate survival benefit in Phase 3 trial in treatment naïve advanced melanoma

News provided by

Bristol-Myers Squibb Canada

Nov 19, 2014, 05:59 ET